Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes

By S. Laing, A. Swerdlow, S. Slater, A. Burden, Andrew D. Morris, N. Waugh, W. Gatling, P. Bingley, C. Patterson. Diabetologia, 2003

761 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/38c1a1b38a15608e6b124b264d4a5b981cba5598

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Marja-Riitta Taskinen
2. J. Forbes
3. I. Graham
4. M. Cooper
5. Alberico L. Catapano
6. Rhian M. Touyz

Citations in the corpus

• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “4 Type 1 diabetes Type 1 diabetes is associated with high CVD risk, in particular in patients with microalbuminuria and renal disease.(355) Conclusive evidence supports the proposition that hyperglycaemia accelerates atherosclerosis.”
• Mechanisms of diabetic complications. (2013, background): “CVD accounts for more than half of the mortality seen in the diabetic population (228, 319), and diabetes equates to an approximately threefold increased risk of myocardial infarction compared with the general population (155).”
• Machine Learning and Data Mining Methods in Diabetes Research (2017, background): “Heart-related abnormalities are considered as commo n diabetic complications [91].”
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “Type 1 diabetes Type 1 diabetes is associated with high CVD risk, in particular in patients with microalbuminuria and renal disease.(177) Conclusive evidence supports the proposition that hyperglycaemia accelerates atherosclerosis.”
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “T1DM is associated with high CVD risk, in particular in patients with microalbuminuria and renal disease.(427) Conclusive evidence supports the proposition that hyperglycaemia accelerates atherosclerosis.”